id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC7760865 | core_pubmed_pmc | Low Oral Bioavailability and Partial Gut Microbiotic and Phase II Metabolism of Brussels/Witloof Chicory Sesquiterpene Lactones in Healthy Humans | Low Oral Bioavailability and Partial Gut Microbiotic and Phase II Metabolism of Brussels/Witloof Chicory Sesquiterpene Lactones in Healthy Humans Abstract Free and glycosylated sesquiterpene lactones (SLs), which are abundant in leafy vegetables including Brussels/witloof chicory, possess health-promoting effects in vi... |
PMC6787415 | core_pubmed_pmc | Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients | Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients Abstract Abstract Donepezil is one of the cholinesterase inhibitors that are indicated for the treatment of mild to moderate Alzheimer's disease (AD). Pharmacokinetic analysis has shown that donepezil is primarily eliminated by renal excretion rat... |
PMC8206290 | core_pubmed_pmc | Clinical Pharmacokinetics of Oral Sodium Selenite and Dosing Implications in the Treatment of Patients with Metastatic Cancer | Clinical Pharmacokinetics of Oral Sodium Selenite and Dosing Implications in the Treatment of Patients with Metastatic Cancer Abstract Abstract Background Selenite is a radiosensitizer and inhibitor of androgen receptor expression and function. In a phase I study ( NCT02184533 ) in 15 subjects with metastatic cancer re... |
PMC5351011 | core_pubmed_pmc | A Phase I Randomized Study of a Specifically Engineered, pH‐Sensitive PCSK9 Inhibitor RN317 (PF‐05335810) in Hypercholesterolemic Subjects on Statin Therapy | A Phase I Randomized Study of a Specifically Engineered, pH‐Sensitive PCSK9 Inhibitor RN317 (PF‐05335810) in Hypercholesterolemic Subjects on Statin Therapy Abstract Abstract This phase I study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of RN317 (PF‐05335810), a specifically engineered, p... |
PMC6983930 | core_pubmed_pmc | Bioactive indanes: Development and validation of an LC-MS/MS bioanalytical method for the determination of PH46A, a new potential anti-inflammatory agent, in dog and rat plasma and its application to a pharmacokinetic study in dog | Bioactive indanes: Development and validation of an LC-MS/MS bioanalytical method for the determination of PH46A, a new potential anti-inflammatory agent, in dog and rat plasma and its application to a pharmacokinetic study in dog Abstract Highlights • Selective and sensitive determination by LC—MS/MS of PH46A, a new c... |
PMC9049199 | core_pubmed_pmc | Simultaneous quantification of five biomarkers in ethanolic extract of Cassia occidentalis Linn. stem using liquid chromatography tandem mass spectrometry: application to its pharmacokinetic studies | Simultaneous quantification of five biomarkers in ethanolic extract of Cassia occidentalis Linn. stem using liquid chromatography tandem mass spectrometry: application to its pharmacokinetic studies Abstract Cassia occidentalis L. stem extract is used as a purgative, febrifuge, and diuretic, and in the treatment of flu... |
PMC6777137 | core_pubmed_pmc | A Physiology-Based Model of Human Bile Acid Metabolism for Predicting Bile Acid Tissue Levels After Drug Administration in Healthy Subjects and BRIC Type 2 Patients | A Physiology-Based Model of Human Bile Acid Metabolism for Predicting Bile Acid Tissue Levels After Drug Administration in Healthy Subjects and BRIC Type 2 Patients Abstract Drug-induced liver injury (DILI) is a matter of concern in the course of drug development and patient safety, often leading to discontinuation of ... |
PMC9391940 | core_pubmed_pmc | In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies | In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies Abstract Abstract Background Since the last COVID-19 outbreak, several approaches have been given a try to quickly tackle ... |
PMC5563351 | core_pubmed_pmc | Pharmacokinetics of Rytary ® , An Extended-Release Capsule Formulation of Carbidopa–Levodopa | Pharmacokinetics of Rytary ® , An Extended-Release Capsule Formulation of Carbidopa–Levodopa Abstract Abstract Parkinson’s disease (PD) is a chronic progressive neurological disorder characterized by resting tremor, rigidity, bradykinesia, gait disturbance, and postural instability. Levodopa, the precursor to dopamine,... |
PMC5948259 | core_pubmed_pmc | A phase I study to assess the mass balance, excretion, and pharmacokinetics of [ 14 C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors | A phase I study to assess the mass balance, excretion, and pharmacokinetics of [ 14 C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors Abstract Summary This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics (PK), and safety of ixazomib in patients with advanc... |
PMC7549214 | core_pubmed_pmc | Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria | Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria Abstract Abstract Background Emergence of anti-malarial drug resistance and perpetual increase in malaria incidence necessitates the development of novel anti-malarials. Histone deacetylases (HDAC) has been shown... |
PMC9200067 | core_pubmed_pmc | Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations | Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations Abstract Abstract Trazodone is approved for the treatment of major depressive disorders, marketed as immediate release (IR), prolonged release, and once a day (OAD) formulation. The different formulations allow different ... |
PMC11858278 | core_pubmed_pmc | Environmentally Friendly Synthesis of New Mono- and Bis-Pyrazole Derivatives; In Vitro Antimicrobial, Antifungal, and Antioxidant Activity; and In Silico Studies: DFT, ADMETox, and Molecular Docking | Environmentally Friendly Synthesis of New Mono- and Bis-Pyrazole Derivatives; In Vitro Antimicrobial, Antifungal, and Antioxidant Activity; and In Silico Studies: DFT, ADMETox, and Molecular Docking Abstract Abstract Background/Objectives: Antimicrobial resistance and oxidative stress are major global health challenges... |
PMC10810248 | core_pubmed_pmc | Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial | Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial Abstract Abstract Background Due to their potential impact on mood and wellbeing there has been increasing interest in the potential of serotonergic... |
PMC7911036 | core_pubmed_pmc | Quantification of BNN27, a novel neuroprotective 17‐spiroepoxy dehydroepiandrosterone derivative in the blood and retina of rodents, after single intraperitoneal administration | Quantification of BNN27, a novel neuroprotective 17‐spiroepoxy dehydroepiandrosterone derivative in the blood and retina of rodents, after single intraperitoneal administration Abstract Abstract BNN27 is a novel 17‐spiroepoxy derivative of the neurosteroid Dehydroepiandrosterone with neuroprotective properties. The pur... |
PMC9041753 | core_pubmed_pmc | Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation | Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation Abstract Abstract Celecoxib (CLB) is a highly hydrophobic selective cyclo-oxygenase inhibitor with high plasma protein binding and undergoes extensive hepatic metabolism. CLB is highly effective in the treatment of osteo and rheu... |
PMC9669261 | core_pubmed_pmc | Efficacy and Pharmacodynamic Target Attainment for Ceftazidime–Avibactam Off-Label Dose Regimens in Patients with Continuous or Intermittent Venovenous Hemodialysis: Two Case Reports | Efficacy and Pharmacodynamic Target Attainment for Ceftazidime–Avibactam Off-Label Dose Regimens in Patients with Continuous or Intermittent Venovenous Hemodialysis: Two Case Reports Abstract Abstract Limited data are available for ceftazidime–avibactam (CZA) dosing in patients receiving renal replacement therapy, espe... |
PMC11618211 | core_pubmed_pmc | Pharmacodynamics (PD), Pharmacokinetics (PK) and PK-PD Modeling of NRF2 Activating Dietary Phytochemicals in Cancer Prevention and in Health | Pharmacodynamics (PD), Pharmacokinetics (PK) and PK-PD Modeling of NRF2 Activating Dietary Phytochemicals in Cancer Prevention and in Health Abstract Purpose of Review Dietary phytochemicals, bioactive compounds derived from plants, have gained increasing attention for their potential role in cancer prevention. Among t... |
PMC7246848 | core_pubmed_pmc | Comparative Cerebroprotective Potential of d - and l -Carnosine Following Ischemic Stroke in Mice | Comparative Cerebroprotective Potential of d - and l -Carnosine Following Ischemic Stroke in Mice Abstract l -carnosine is an attractive therapeutic agent for acute ischemic stroke based on its robust preclinical cerebroprotective properties and wide therapeutic time window. However, large doses are needed for efficacy... |
PMC11813913 | core_pubmed_pmc | Population dynamics analysis of the interaction between tacrolimus and voriconazole in renal transplant recipients | Population dynamics analysis of the interaction between tacrolimus and voriconazole in renal transplant recipients Abstract Abstract Background The concurrent administration of tacrolimus and voriconazole in kidney transplant recipients can lead to drug interactions, potentially resulting in severe adverse reactions. T... |
PMC12034845 | core_pubmed_pmc | Utilizing Physiologically Based Pharmacokinetic Models to Support Rational Medication in Chinese Elderly Population | Utilizing Physiologically Based Pharmacokinetic Models to Support Rational Medication in Chinese Elderly Population Abstract Background China is undergoing a pronounced shift towards an aging society, wherein the elderly constitute a prominent demographic relying significantly on medications. The imperative of administ... |
PMC12513044 | core_pubmed_pmc | Effects of Lacosamide, Pregabalin, and Tapentadol on Peripheral Nerve Excitability: A Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Trial in Healthy Subjects | Effects of Lacosamide, Pregabalin, and Tapentadol on Peripheral Nerve Excitability: A Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Trial in Healthy Subjects Abstract Abstract Background: Chronic pain is a leading cause of disability globally, with limited treatment options and frequent adverse e... |
PMC11562027 | core_pubmed_pmc | Development of ion-triggered in situ gel containing ketoconazole/hydroxypropyl-β-cyclodextrin for ocular delivery: in vitro and in vivo evaluation | Development of ion-triggered in situ gel containing ketoconazole/hydroxypropyl-β-cyclodextrin for ocular delivery: in vitro and in vivo evaluation Abstract Abstract The application of ketoconazole (KET) in ocular drug delivery is restricted by its poor aqueous solubility though its broad-spectrum antifungal activity. T... |
PMC9828147 | core_pubmed_pmc | DFinder: a novel end-to-end graph embedding-based method to identify drug–food interactions | DFinder: a novel end-to-end graph embedding-based method to identify drug–food interactions Abstract Abstract Motivation Drug–food interactions (DFIs) occur when some constituents of food affect the bioaccessibility or efficacy of the drug by involving in drug pharmacodynamic and/or pharmacokinetic processes. Many comp... |
PMC12358300 | core_pubmed_pmc | Evaluation of Four Semi‐Mechanistic Models for Predicting Glycemic Control With a Glucagon Receptor Antagonist in People With Type 2 Diabetes | Evaluation of Four Semi‐Mechanistic Models for Predicting Glycemic Control With a Glucagon Receptor Antagonist in People With Type 2 Diabetes Abstract ABSTRACT Glycated hemoglobin (HbA1c) is the gold standard for measuring long‐term glycemic efficacy over at least 3 months in Type 2 diabetes (T2D). Being able to predic... |
PMC11574905 | core_pubmed_pmc | Unlocking Benzosampangine’s Potential: A Computational Approach to Investigating, Its Role as a PD-L1 Inhibitor in Tumor Immune Evasion via Molecular Docking, Dynamic Simulation, and ADMET Profiling | Unlocking Benzosampangine’s Potential: A Computational Approach to Investigating, Its Role as a PD-L1 Inhibitor in Tumor Immune Evasion via Molecular Docking, Dynamic Simulation, and ADMET Profiling Abstract Abstract The interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1 plays a crucial rol... |
PMC7791651 | core_pubmed_pmc | Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects | Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects Abstract Background A once-daily (o.d.) fixed-dose combination of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF) deliv... |
PMC8679518 | core_pubmed_pmc | Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study | Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study Abstract Abstract Angiotensin-converting enzyme 2 (ACE2) is the first target of SARS-CoV-2 and a key functional h... |
PMC3675301 | core_pubmed_pmc | Long-Term Anticoagulation in the Extreme Elderly with the Newer Antithrombotics: Safe or Sorry? | Long-Term Anticoagulation in the Extreme Elderly with the Newer Antithrombotics: Safe or Sorry? Abstract Background and Objectives The prevalence of atrial fibrillation (AF) doubles in the extreme elderly and is higher than in the rest of the population. Warfarin therapy to prevent thromboembolic events secondary to AF... |
PMC3644256 | core_pubmed_pmc | Evaluation of propofol anesthesia in morbidly obese children and adolescents | Evaluation of propofol anesthesia in morbidly obese children and adolescents Abstract Background Poor characterization of propofol pharmacokinetics and pharmacodynamics in the morbidly obese (MO) pediatric population poses dosing challenges. This study was conducted to evaluate propofol total intravenous anesthesia (TI... |
PMC9237441 | core_pubmed_pmc | Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities | Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities Abstract Vitamin K2-7, also known as menaquinone-7 (MK-7) is a form of vitamin K that has health-beneficial effects in osteoporosis, cardiovascular disease, inflammation, cancer, Alzheimer’s disease, diabete... |
PMC12009869 | core_pubmed_pmc | Paeoniflorin: a review of its pharmacology, pharmacokinetics and toxicity in diabetes | Paeoniflorin: a review of its pharmacology, pharmacokinetics and toxicity in diabetes Abstract Abstract The escalating global prevalence of diabetes underscores the urgency of addressing its treatment and associated complications. Paeoniflorin, a monoterpenoid glycoside compound, has garnered substantial attention in r... |
PMC6133194 | core_pubmed_pmc | Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia | Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia Abstract Supplemental digital content is available in the text. Abstract Background Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia, re... |
PMC6359037 | core_pubmed_pmc | Effects of Piperazine Derivative on Paclitaxel Pharmacokinetics | Effects of Piperazine Derivative on Paclitaxel Pharmacokinetics Abstract Paclitaxel (PTX) is an anticancer agent that is used to treat many cancers but it has a very low oral bioavailability due, at least in part, to the drug efflux transporter, P-glycoprotein (P-gp). Therefore, this study was performed to enhance oral... |
PMC11245884 | core_pubmed_pmc | Difficulties associated with the interpretation of postmortem toxicology | Difficulties associated with the interpretation of postmortem toxicology Abstract Abstract While postmortem (PM) toxicology results provide valuable information towards ascertaining both the cause and manner of death in coronial cases, there are also significant difficulties associated with the interpretation of PM dru... |
PMC7602742 | core_pubmed_pmc | Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice | Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice Abstract Abstract MBQ-167 is a dual inhibitor of the Rho GTPases Rac and Cdc42 that has shown promising results as an anti-cancer therapeutic at the preclinical stage. This drug has been tested in vitro and... |
PMC6143907 | core_pubmed_pmc | Combination of magnetic resonance imaging and targeted contrast agent for the diagnosis of myocardial infarction | Combination of magnetic resonance imaging and targeted contrast agent for the diagnosis of myocardial infarction Abstract Abstract Myocardial infarction is one of the most common human cerebrovascular conditions and frequently leads to ischemic stroke. Evidence has indicated that magnetic resonance imaging (MRI) is a p... |
PMC10819565 | core_pubmed_pmc | Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib | Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib Abstract Abstract Dacomitinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) and EGFR-activating mutations. Proton-pump inhibit... |
PMC11762574 | core_pubmed_pmc | Relative Forgiveness of Different Allopurinol Implementation Patterns in People with Gout and their Impact on Clinical Outcomes: a Simulation Study | Relative Forgiveness of Different Allopurinol Implementation Patterns in People with Gout and their Impact on Clinical Outcomes: a Simulation Study Abstract Abstract Background and Objective Adherence to urate-lowering therapy among people with gout is poor, so it is important to understand which day-to-day medication-... |
PMC9271885 | core_pubmed_pmc | Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2 | Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2 Abstract Summary Background To address the emergence of SARS-CoV-2, multiple clinical trials in humans were rapidly started, including those involving an oral treatment by nitazoxanide, despite no or limited pre-clinical evidence of antivi... |
PMC3306781 | core_pubmed_pmc | First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development | First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development Abstract Dose selection for “first in children” trials often relies on scaling of the pharmacokinetics from adults to children. Commonly used approaches are physiologically-based ... |
PMC12239117 | core_pubmed_pmc | The pharmacokinetics of hexylresorcinol-containing lozenges and their antimicrobial efficacy against oral and respiratory microorganisms | The pharmacokinetics of hexylresorcinol-containing lozenges and their antimicrobial efficacy against oral and respiratory microorganisms Abstract ABSTRACT Background Hexylresorcinol (HR) lozenges provide symptomatic relief for sore throats. Despite its recognised anaesthetic and antiseptic properties, evidence of HR ba... |
PMC3459840 | core_pubmed_pmc | Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes , a potential antitumor drug | Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes , a potential antitumor drug Abstract Abstract Purpose To investigate the growth inhibition activity of Flammulina velutipes sterol (FVS) against certain human cancer cell lines (gastric SGC and colon LoVo) and to evaluat... |
PMC8911561 | core_pubmed_pmc | Quantification of Venetoclax for Therapeutic Drug Monitoring in Chinese Acute Myeloid Leukemia Patients by a Validated UPLC-MS/MS Method | Quantification of Venetoclax for Therapeutic Drug Monitoring in Chinese Acute Myeloid Leukemia Patients by a Validated UPLC-MS/MS Method Abstract Venetoclax has emerged as a breakthrough for treatment of leukemia with a wide interindividual variability in pharmacokinetics. Herein, a rapid, sensitive, and reliable UPLC-... |
PMC12932621 | core_pubmed_pmc | Therapeutic drug monitoring of daptomycin in a critically ill patient cohort | Therapeutic drug monitoring of daptomycin in a critically ill patient cohort Abstract Background Pharmacokinetics of antimicrobial agents are altered in critically ill patients. Therefore, therapeutic drug monitoring (TDM) has gained much attention in recent years. Specifically, the role of TDM for daptomycin, its pote... |
PMC4467250 | core_pubmed_pmc | Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls | Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls Abstract This study evaluated dolutegravir pharmacokinetics (PK) in subjects with moderate hepatic impairment compared to matched, healthy controls. In this open-label, paralle... |
PMC10842770 | core_pubmed_pmc | Photobac derived from bacteriochlorophyll-a shows potential for treating brain tumor in animal models by photodynamic therapy with desired pharmacokinetics and limited toxicity in rats and dogs | Photobac derived from bacteriochlorophyll-a shows potential for treating brain tumor in animal models by photodynamic therapy with desired pharmacokinetics and limited toxicity in rats and dogs Abstract Photobac is a near infrared photosensitizer (PS) derived from naturally occurring bacteriochlorophyll-a, with a poten... |
PMC6276942 | core_pubmed_pmc | Closed-Loop Intravenous Drug Administration Using Photoplethysmography | Closed-Loop Intravenous Drug Administration Using Photoplethysmography Abstract Abstract An optically-based injection control system has been developed for preclinical use for an intravenous drug delivery application. Current clinical drug delivery for oncology typically provides for intravenous administration without ... |
PMC4546409 | core_pubmed_pmc | Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies | Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies Abstract Abstract CC-486 (oral azacitidine) is an epigenetic modifier in development for patients with myelodysplastic syndromes and acute myeloid leukemia. In part 1 of this two-part study, a 7-day CC-486 dos... |
PMC7066107 | core_pubmed_pmc | Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours | Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours Abstract Summary Navoximod (GDC-0919) is a small molecule inhibitor of indoleamine-2,3-dioxygenase 1. This study inve... |
PMC5073492 | core_pubmed_pmc | Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion | Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion Abstract Introduction Liver cirrhosis can have a major impact on drug pharmacokinetics and pharmacodynamics. Patients with cirrhosis often suffer from potentially preventable adverse drug reactions. Guidel... |
PMC9683076 | core_pubmed_pmc | Effects of a ritonavir‐containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects | Effects of a ritonavir‐containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects Abstract Abstract The immunosuppressive agents sirolimus and everolimus are sensitive CYP3A4 substrates with narrow therapeutic index. Ritonavir is a strong CYP3A inhibitor. A phase 1 study was conduct... |
PMC11152975 | core_pubmed_pmc | Polycaprolactone – Vitamin E TPGS micelles for delivery of paclitaxel: In vitro and in vivo evaluation | Polycaprolactone – Vitamin E TPGS micelles for delivery of paclitaxel: In vitro and in vivo evaluation Abstract This study aimed to present findings on a paclitaxel (PTX)-loaded polymeric micellar formulation based on polycaprolactone-vitamin E TPGS (PCL-TPGS) and evaluate its in vitro anticancer activity as well as it... |
PMC5093939 | core_pubmed_pmc | Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration | Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration Abstract Abstract Background Staphylococci represent the first etiologic agents of bone and joint infection (BJI), leading glycopeptides use, especially in case ... |
PMC10955611 | core_pubmed_pmc | Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers | Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers Abstract Abstract PF614, a trypsin‐activated abuse protection oxycodone prodrug designed to reduce recreational drug abuse, was compared to OxyContin for safe... |
PMC3896282 | core_pubmed_pmc | Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers | Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers Abstract Abstract Background This study was conducted to compare the oral bioavailability of an itopride extended-release (ER) formulation with that of the ... |
PMC8286234 | core_pubmed_pmc | Bioanalysis of niclosamide in plasma using liquid chromatography-tandem mass and application to pharmacokinetics in rats and dogs | Bioanalysis of niclosamide in plasma using liquid chromatography-tandem mass and application to pharmacokinetics in rats and dogs Abstract Niclosamide, which is an anti-tapeworm drug, was developed in 1958. However, recent studies have demonstrated the antiviral effects of niclosamide against the SARS-CoV-2 virus, whic... |
PMC5510082 | core_pubmed_pmc | Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome | Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome Abstract Abstract Aims Pharmacokinetic (PK) studies suggest that there is a room for improvement in clinical use of rituximab through more individualized treatment. The objective of this study w... |
PMC7443423 | core_pubmed_pmc | Optimizing Predictive Performance of Bayesian Forecasting for Vancomycin Concentration in Intensive Care Patients | Optimizing Predictive Performance of Bayesian Forecasting for Vancomycin Concentration in Intensive Care Patients Abstract Purpose Bayesian forecasting is crucial for model-based dose optimization based on therapeutic drug monitoring (TDM) data of vancomycin in intensive care (ICU) patients. We aimed to evaluate the pe... |
PMC11790873 | core_pubmed_pmc | Regulation of adipocyte differentiation and lipid metabolism by novel synthetic chromenes exploring anti-obesity and broader therapeutic potential | Regulation of adipocyte differentiation and lipid metabolism by novel synthetic chromenes exploring anti-obesity and broader therapeutic potential Abstract Abstract Obesity poses a significant global health challenge, necessitating the search for novel therapeutic agents to address this epidemic. Chromenes, known for t... |
PMC3111455 | core_pubmed_pmc | Matrix Metalloproteinase-8 Mediates the Unfavorable Systemic Impact of Local Irradiation on Pharmacokinetics of Anti-Cancer Drug 5-Fluorouracil | Matrix Metalloproteinase-8 Mediates the Unfavorable Systemic Impact of Local Irradiation on Pharmacokinetics of Anti-Cancer Drug 5-Fluorouracil Abstract Abstract Concurrent chemoradiation with 5-fluorouracil (5-FU) is widely accepted for cancer treatment. However, the interactions between radiation and 5-FU remain uncl... |
PMC10212792 | core_pubmed_pmc | A detailed biochemical characterization, toxicological assessment and molecular docking studies of Launaea fragilis : An important medicinal xero-halophyte | A detailed biochemical characterization, toxicological assessment and molecular docking studies of Launaea fragilis : An important medicinal xero-halophyte Abstract Abstract Launaea fragilis (Asso) Pau (Family: Asteraceae) is a wild medicinal plant that has been used in the folklore as a potential treatment for numerou... |
PMC4622453 | core_pubmed_pmc | Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures | Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures Abstract Abstract Brivaracetam (BRV), a high-affinity synaptic vesicle protein 2A ligand, reported to be 10–30-fold more potent than levetiracetam (LEV), is highly effective in a wide range of experi... |
PMC11253374 | core_pubmed_pmc | Modelling the nicotine pharmacokinetic profile for e-cigarettes using real time monitoring of consumers’ physiological measurements and mouth level exposure | Modelling the nicotine pharmacokinetic profile for e-cigarettes using real time monitoring of consumers’ physiological measurements and mouth level exposure Abstract Abstract Pharmacokinetic (PK) studies can provide essential information on abuse liability of nicotine and tobacco products but are intrusive and must be ... |
PMC12775995 | core_pubmed_pmc | Synthesis, characterization, and anticancer evaluation of N- Heterocyclic entities: ADME profiling and In Silico predictions | Synthesis, characterization, and anticancer evaluation of N- Heterocyclic entities: ADME profiling and In Silico predictions Abstract This study aimed to synthesize a novel series of N -heterocyclic compounds and evaluate their integrated pharmacological potential by coupling in vitro selective cytotoxicity on tumor an... |
PMC4816034 | core_pubmed_pmc | Tolerability and pharmacokinetics of oxaloacetate 100 mg capsules in Alzheimer's subjects | Tolerability and pharmacokinetics of oxaloacetate 100 mg capsules in Alzheimer's subjects Abstract Abstract Bioenergetics and bioenergetic-related functions are altered in Alzheimer's disease (AD) subjects. These alterations represent therapeutic targets and provide an underlying rationale for modifying brain bioenerge... |
PMC7719384 | core_pubmed_pmc | Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin | Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin Abstract Xanthine oxidase inhibitors febuxostat and allopurinol are commonly used in the treatment of gout. Febuxostat inhibits the breast cancer resistance protein (BCRP) in vitro .... |
PMC8492975 | core_pubmed_pmc | Methylprednisolone in Pediatric Cardiac Surgery: Is There Enough Evidence? | Methylprednisolone in Pediatric Cardiac Surgery: Is There Enough Evidence? Abstract Abstract Corticosteroids have been used to decrease the inflammatory response to cardiac surgery and cardiopulmonary bypass in children for decades. Sparse information is present concerning the pharmacokinetics and pharmacodynamics of c... |
PMC4615734 | core_pubmed_pmc | First-in-human uPAR PET: Imaging of Cancer Aggressiveness | First-in-human uPAR PET: Imaging of Cancer Aggressiveness Abstract A first-in-human clinical trial with Positron Emission Tomography (PET) imaging of the urokinase-type plasminogen activator receptor (uPAR) in patients with breast, prostate and bladder cancer, is described. uPAR is expressed in many types of human canc... |
PMC6913762 | core_pubmed_pmc | Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats | Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats Abstract Background Eliglustat, a new oral substrate-reduction therapy, was recently approved as a first-line therapy for Gaucher's disease type 1 (GD1) patients. Purpose The purpose of the present study was to develop and ... |
PMC4996894 | core_pubmed_pmc | Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium | Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium Abstract Introduction Because the multimodal antidepressant vortioxetine is likely to be coadministered with other central nervous system (CNS)-active drugs, potential drug–drug interactions warrant examination... |
PMC6944222 | core_pubmed_pmc | Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans | Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans Abstract Abstract To address concerns around age-related sensitivity to pyrethroids, a life-stage physiologically based pharmacokinetic (PBPK) model, supported by in... |
PMC12952245 | core_pubmed_pmc | Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938) | Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938) Abstract Abstract Background: Ataxia telangiectasia and Rad3-related (ATR) inhibition with berzosertib potentiates the efficacy of irinotecan in preclinical mode... |
PMC10832099 | core_pubmed_pmc | Two rare flavonoid glycosides from Litsea glutinosa (Lour.) C. B. Rob.: experimental and computational approaches endorse antidiabetic potentiality | Two rare flavonoid glycosides from Litsea glutinosa (Lour.) C. B. Rob.: experimental and computational approaches endorse antidiabetic potentiality Abstract Background Litsea glutinosa (Lour.) C. B. Rob. belongs to the Litsea genus and is categorized under the family of Lauraceae . The study aimed to investigate the ph... |
PMC5500557 | core_pubmed_pmc | Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation | Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation Abstract Background Dicloxacillin, a semisynthetic isoxazolyl penicillin, exhibits antimicrobial activity against a wide variety of Gram-positive bacteria, as well as stability against penicillinases and low level of... |
PMC10188401 | core_pubmed_pmc | Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis | Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis Abstract Abstract Introduction The terminal complement C5 inhibitor ravulizumab has a long elimination half-life, allowing maintenance dosing every 8 weeks. In the 26-week, double-blind, randomized, placebo-controlled perio... |
PMC5080817 | core_pubmed_pmc | Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial | Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial Abstract Purpose The purpose of this study is to investigate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and plasma cytokines and angiog... |
PMC10459920 | core_pubmed_pmc | Efficacy, Pharmacokinetics, and Toxicity Profiles of a Broad Anti-SARS-CoV-2 Neutralizing Antibody | Efficacy, Pharmacokinetics, and Toxicity Profiles of a Broad Anti-SARS-CoV-2 Neutralizing Antibody Abstract Abstract We recently reported the isolation and characterization of an anti-SARS-CoV-2 antibody, called IgG-A7, that protects transgenic mice expressing the human angiotensin-converting enzyme 2 (hACE-2) from an ... |
PMC8868383 | core_pubmed_pmc | Pharmacokinetics and Pharmacodynamics of Key Components of a Standardized Centella asiatica Product in Cognitively Impaired Older Adults: A Phase 1, Double-Blind, Randomized Clinical Trial | Pharmacokinetics and Pharmacodynamics of Key Components of a Standardized Centella asiatica Product in Cognitively Impaired Older Adults: A Phase 1, Double-Blind, Randomized Clinical Trial Abstract Abstract Centella asiatica is reputed in Eastern medicine to improve cognitive function in humans. Preclinical studies hav... |
PMC4487954 | core_pubmed_pmc | Laparoscopic Salpingo-oophorectomy in Conscious Sedation | Laparoscopic Salpingo-oophorectomy in Conscious Sedation Abstract Introduction: Conscious sedation has traditionally been used for laparoscopic tubal ligation. General anesthesia with endotracheal intubation may be associated with side effects, such as nausea, vomiting, cough, and dizziness, whereas sedation offers the... |
PMC10780175 | core_pubmed_pmc | In Silico and In Vivo Pharmacokinetic Evaluation of 84-B10, a Novel Drug Candidate against Acute Kidney Injury and Chronic Kidney Disease | In Silico and In Vivo Pharmacokinetic Evaluation of 84-B10, a Novel Drug Candidate against Acute Kidney Injury and Chronic Kidney Disease Abstract Acute kidney injury (AKI) and chronic kidney disease (CKD) have become public health problems due to high morbidity and mortality. Currently, drugs recommended for patients ... |
PMC3750714 | core_pubmed_pmc | Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance? | Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance? Abstract Abstract Since low-molecular-weight heparins (LMWHs) are eliminated preferentially via the kidneys, the potential for accumulation of these agents (and an increased risk of bleeding) is of p... |
PMC8055417 | core_pubmed_pmc | Network Pharmacology and Molecular Docking Suggest the Mechanism for Biological Activity of Rosmarinic Acid | Network Pharmacology and Molecular Docking Suggest the Mechanism for Biological Activity of Rosmarinic Acid Abstract Abstract Rosmarinic acid (RosA) is a natural phenolic acid compound, which is mainly extracted from Labiatae and Arnebia . At present, there is no systematic analysis of its mechanism. Therefore, we used... |
PMC6710810 | core_pubmed_pmc | Effects of Xuesaitong on the Pharmacokinetics of Losartan: An In Vivo UPLC-MS/MS Study | Effects of Xuesaitong on the Pharmacokinetics of Losartan: An In Vivo UPLC-MS/MS Study Abstract Abstract The aim of this study was to examine whether Xuesaitong, a multiherbal formulation for coronary heart disease, alters the pharmacokinetics of losartan. Adult male Sprague Dawley rats randomly received losartan (10 m... |
PMC6027739 | core_pubmed_pmc | Confidence and Prediction Intervals for Pharmacometric Models | Confidence and Prediction Intervals for Pharmacometric Models Abstract Abstract Supporting decision making in drug development is a key purpose of pharmacometric models. Pharmacokinetic models predict exposures under alternative posologies or in different populations. Pharmacodynamic models predict drug effects based o... |
PMC9523648 | core_pubmed_pmc | Teaching resources for the European Open Platform for Prescribing Education (EurOP 2 E)—a nominal group technique study | Teaching resources for the European Open Platform for Prescribing Education (EurOP 2 E)—a nominal group technique study Abstract The European Open Platform for Prescribing Education (EurOP 2 E) seeks to improve and harmonize European clinical pharmacology and therapeutics (CPT) education by facilitating international c... |
PMC8434701 | core_pubmed_pmc | PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models | PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models Abstract Abstract Background Scarce drug penetration in solid tumours is one of the possible causes of the limited efficacy of chemotherapy and is related to the altered ... |
PMC6382135 | core_pubmed_pmc | Metal based donepezil analogues designed to inhibit human acetylcholinesterase for Alzheimer’s disease | Metal based donepezil analogues designed to inhibit human acetylcholinesterase for Alzheimer’s disease Abstract Abstract Among neurodegenerative disorders, Alzheimer’s disease (AD) is one of the most common disorders showing slow progressive cognitive decline. Targeting acetylcholinesterase (AChE) is one of the major s... |
PMC4226840 | core_pubmed_pmc | An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer | An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer Abstract Summary Background This phase I study evaluated the pharmacokinetics and pharmacodynamics of CEP-11981, an oral vascular endothelial growth factor (VEGF) tyrosin... |
PMC11380098 | core_pubmed_pmc | Drug-Drug Interactions and the Clinical Tolerability of Colchicine Among Patients With COVID-19 | Drug-Drug Interactions and the Clinical Tolerability of Colchicine Among Patients With COVID-19 Abstract Key Points Question Are drug-drug interactions associated with the clinical safety and efficacy of colchicine in people with COVID-19? Findings In this secondary analysis of the COLCORONA trial including 4432 patien... |
PMC11842173 | core_pubmed_pmc | Why the racing industry and equestrian disciplines need to implement population pharmacokinetics: To learn, explain, summarize, harmonize, and individualize | Why the racing industry and equestrian disciplines need to implement population pharmacokinetics: To learn, explain, summarize, harmonize, and individualize Abstract Abstract Population pharmacokinetics (POP PK) is a powerful pharmacokinetic tool, which measures quantitatively, and explains the variability in drug expo... |
PMC5018035 | core_pubmed_pmc | Pharmacokinetics of heroin and its metabolites in vitreous humor and blood in a living pig model | Pharmacokinetics of heroin and its metabolites in vitreous humor and blood in a living pig model Abstract Abstract Vitreous humor (VH) is an alternative matrix for drug analysis in forensic toxicology. However, little is known about the distribution of xenobiotics, such as opioids, into VH in living organisms. The aim ... |
PMC9953069 | core_pubmed_pmc | Molecular Screening of Bioactive Compounds of Garlic for Therapeutic Effects against COVID-19 | Molecular Screening of Bioactive Compounds of Garlic for Therapeutic Effects against COVID-19 Abstract Abstract An outbreak of pneumonia occurred on December 2019 in Wuhan, China, which caused a serious public health emergency by spreading around the globe. Globally, natural products are being focused on more than synt... |
PMC5996271 | core_pubmed_pmc | Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes | Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes Abstract Abstract Ibogaine may be effective for transitioning opioid and cocaine dependent individuals to sobriety. American and European self-help groups provided public testim... |
PMC10069847 | core_pubmed_pmc | Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study | Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study Abstract Abstract Background Long-acting (LA) intramuscular cabotegravir and rilpivirine are prone to drug-drug interactions (DDI). However, given the long dosing interval, ... |
PMC11292200 | core_pubmed_pmc | Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma | Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma Abstract Abstract Purpose: The purpose of the study was to evaluate the relationships between brentuximab vedotin (BV) pharmacokinetic... |
PMC3191584 | core_pubmed_pmc | Pharmacokinetic research in children: an analysis of registered records of clinical trials | Pharmacokinetic research in children: an analysis of registered records of clinical trials Abstract Background Reported off-label/unlicensed prescribing rates in children range from 11% to 80%. Research into pharmacokinetic profiles of children's medicines is essential in the creation of more knowledge on the safety an... |
PMC12775819 | core_pubmed_pmc | Optimizing PSMA-617-based inhibitors through charged linker modifications: Insights into structure-activity relationships | Optimizing PSMA-617-based inhibitors through charged linker modifications: Insights into structure-activity relationships Abstract Abstract Rationale: The introduction of Pluvicto ® ([ 177 Lu]Lu-vipivotide tetraxetan; [ 177 Lu]Lu-PSMA-617) marks a milestone in radioligand therapy (RLT) for PSMA-positive metastatic cast... |
PMC12511116 | core_pubmed_pmc | Neurotherapeutics across blood–brain barrier: screening of BBB-permeable and CNS-active molecules for neurodegenerative disease | Neurotherapeutics across blood–brain barrier: screening of BBB-permeable and CNS-active molecules for neurodegenerative disease Abstract Neurotherapeutics that are effective in the central nervous system (CNS) of the brain require an accurate estimation of their uptake across the blood–brain barrier (BBB), a highly sel... |
PMC9099119 | core_pubmed_pmc | Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals | Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals Abstract Abstract Baloxavir marboxil is an endonuclease inhibitor indicated for the treatment of influenza in patients ≥12 years. No data exist for Chinese patients in global studies. This randomized, ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.